These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 3289191

  • 21. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J, Ringdén O.
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [Abstract] [Full Text] [Related]

  • 22. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R, Deeg HJ, Whitehead J, Farewell V, Appelbaum FR, Beatty P, Bensinger W, Buckner CD, Clift RA, Doney K.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract] [Full Text] [Related]

  • 23. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E, Devergie A, Lokiec F.
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract] [Full Text] [Related]

  • 24. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC.
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [Abstract] [Full Text] [Related]

  • 25. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J, Ringdén O, Heimdahl A, Lönnqvist B, Sundberg B.
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract] [Full Text] [Related]

  • 26. Combination prophylactic immunosuppression in bone marrow transplantation.
    Szer J.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
    [No Abstract] [Full Text] [Related]

  • 27. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [Abstract] [Full Text] [Related]

  • 28. Prevention of graft versus host disease following allogeneic bone marrow transplantation.
    Powles RL, Goss GD, Millar J, Maitland J, Borthwick-Clark C, Al-Jundi A.
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):133-8. PubMed ID: 3914738
    [No Abstract] [Full Text] [Related]

  • 29. Regeneration of genetically restricted immune functions after human bone marrow transplantation: influence of four different strategies for graft-v-host disease prophylaxis.
    Donnenberg AD, Hess AD, Duff SC, Bright EC, Noga SJ, Rowley SD, Saral R, Santos GW.
    Transplant Proc; 1987 Dec; 19(6 Suppl 7):144-52. PubMed ID: 3321641
    [No Abstract] [Full Text] [Related]

  • 30. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation.
    Fay JW, Nash RA, Wingard JR, Przepiorka D, Collins RH, Anasetti C, Devine SM, Piñeiro LA, Storb RF, Aro RM.
    Transplant Proc; 1995 Feb; 27(1):1374. PubMed ID: 7533383
    [No Abstract] [Full Text] [Related]

  • 31. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J, Duerst R, Rapoport A, Constine L, Abboud C, Packman C, Wedow L, Zwetsch L, McKenna B, Linder T, Silverman W, Swift S, Rowe J, DiPersio J.
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [Abstract] [Full Text] [Related]

  • 32. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P, Brugger S, Schwarzinger I, Greinix HT, Keil F, Kyrle PA, Knöbl P, Schneider B, Höcker P, Linkesch W.
    Transplantation; 1995 Nov 15; 60(9):949-57. PubMed ID: 7491699
    [Abstract] [Full Text] [Related]

  • 33. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y, Kanamaru A, Dohy H, Masaoka T, Japanese FK506 BMT(Bone Marrow Transplantation) Study Group.
    Bone Marrow Transplant; 2001 Jul 15; 28(2):181-5. PubMed ID: 11509936
    [Abstract] [Full Text] [Related]

  • 34. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients.
    Hägglund H, Boström L, Ringdén O, Nilsson B, Remberger M.
    Transplant Proc; 1994 Jun 15; 26(3):1821-2. PubMed ID: 8030154
    [No Abstract] [Full Text] [Related]

  • 35. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 36. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ.
    Bone Marrow Transplant; 1998 Mar 15; 21(6):543-51. PubMed ID: 9543057
    [Abstract] [Full Text] [Related]

  • 37. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
    Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A, Gruppo Italiano Trapianti Midollo Osseo (GITMO).
    Biol Blood Marrow Transplant; 2006 May 15; 12(5):560-5. PubMed ID: 16635791
    [Abstract] [Full Text] [Related]

  • 38. Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation.
    Phillips GL, Nevill TJ, Spinelli JJ, Nantel SH, Klingemann HG, Barnett MJ, Shepherd JD, Chan KW, Meharchand JM, Sutherland HJ.
    Bone Marrow Transplant; 1995 Feb 15; 15(2):213-9. PubMed ID: 7539667
    [Abstract] [Full Text] [Related]

  • 39. Prevention of graft-versus-host disease on an individual basis.
    Aschan J, Ringdén O, Andström E, Ljungman P, Remberger M.
    Transplant Proc; 1994 Jun 15; 26(3):1823-4. PubMed ID: 8030155
    [No Abstract] [Full Text] [Related]

  • 40. [Cyclosporine in allogeneic bone marrow transplantation in children].
    Kojima S, Fukuda M, Horibe K, Matsuyama K.
    Rinsho Ketsueki; 1987 Sep 15; 28(9):1576-82. PubMed ID: 3325658
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.